Shorepower Merges with Aeternum Health, Pivots to Longevity Peptide Platform

In a transformative corporate move, Shorepower Technologies (OTC: SPEV) has announced a major merger with Aeternum Health LLC that will fundamentally reshape the company's future. The agreement, dated February 17, 2026, will see Aeternum Health merge into Shorepower, with the surviving entity issuing 51% ownership to Aeternum Health's sole member. This strategic pivot marks a complete departure from Shorepower's current focus on transportation electrification infrastructure toward becoming a longevity and health optimization platform centered on novel peptide technology. The transaction includes the transfer of intellectual property and know-how related to an innovative peptide mix in development for anti-aging applications, along with a minimum $1.5 million cash contribution and a commercialization business for the peptide technology. This information was distributed through PRISM MediaWire, a trusted press release distribution service that ensures wide dissemination of corporate announcements.

The leadership transition accompanying this merger is equally significant, with Jeff Kim resigning as President, CEO, and sole director to be replaced by Paul E. Mann, Manager of Aeternum Health. Mann brings impressive credentials to the role, including over two decades of experience in biotechnology and healthcare investing, current leadership as Chairman and CEO of ASP Isotopes Inc. (Nasdaq: ASPI), and previous senior investment roles at prestigious firms like Soros Fund Management and Morgan Stanley. His background as a research scientist at Procter & Gamble and inventor of multiple skincare formulations provides unique expertise for the company's new direction in health optimization technologies. The corporate restructuring includes a planned name change to Aeternum Health Inc., an increase in authorized common shares to 250 million, and a spin-out of the existing transportation electrification business, creating a clean break from the company's legacy operations.

This merger represents more than just a corporate transaction—it signals the emergence of a new publicly-traded entity focused on the rapidly growing longevity market. Shorepower's complete strategic repositioning from transportation infrastructure to peptide-based health solutions demonstrates how companies are pivoting to capitalize on the booming anti-aging and wellness sectors. The transaction structure, designed to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code, includes substantial voting power through 2,000,000 shares of Series B Preferred Stock, each with voting power equal to 40 shares of common stock. As the company transitions, financial statements and pro forma information will be filed within 71 days of the initial Form 8-K filing, providing investors with crucial transparency about this dramatic corporate transformation. The announcement, which first appeared on Prism Media Wire, represents a watershed moment for both companies and the broader longevity industry.